Skip to main content

Table 2 Inhibition of the Activity of Wild-Type Kit and Primary Activating Kit Mutants by Motesanib and Imatinib*

From: Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

  IC50 of Kit Autophosphorylation, nM IC50 of Stably Transfected Ba/F3 Cell Survival, nM
KIT Genotype Motesanib Imatinib Motesanib Imatinib
Wild-type 36 165 - -
V560D 5 18 3 7
Δ552-559 1 5 0.4 1
AYins503-504 18 84 11 47
  1. *In autophosphorylation experiments, means from 2 experiments are shown, with the exception of Δ552-559, which was assessed once. Viability experiments were performed once.